Unrelated umbilical cord blood (UCB) is an alternative stem cell source for paediatric patients lacking a matched related or unrelated marrow donor. We report the results of all paediatric unrelated UCB transplants performed in Australia and New Zealand over a 10-year period. A total of 135 patients were transplanted, 100 for malignant disease (74%) and 35 for non-malignant disorders. The majority (88%) of patients received an HLA-mismatched graft. The median infused total nucleated cell dose was 4.7 Â 10 7 /kg and CD34 þ count 1.9 Â 10 5 /kg. Neutrophil engraftment occurred in 83% of patients by day 42 (median 23 days) and platelet engraftment in 55% by day 60 (median 56 days). Grades II-IV and III-IV acute GVHD occurred in 41 and 18% of patients, respectively. TRM and overall survival 1-year post transplant were 32 and 61%, respectively. A higher probability of neutrophil recovery (P ¼ 0.004) and faster time to recovery (median 18 days vs 26 days, P ¼ 0.008) were observed in recipients of a cord unit with a CD34 cell dose X1.7 Â 10 5 /kg. Our results support selection of cord units with CD34 cell doses X1.7 Â 10 5 /kg to promote faster engraftment, improve survival and lower TRM.
Introduction
Over the past decade, unrelated donor umbilical cord blood (UCB) has been increasingly used as an alternative stem cell source for patients lacking HLA-matched BM donors. [1] [2] [3] [4] [5] [6] [7] Unrelated UCB has been used successfully for patients with a range of malignant and non-malignant diseases including leukaemia and lymphoma, constitutional and acquired BM failure syndromes, severe congenital immunodeficiency syndromes, haemoglobinopathies and selected metabolic disorders. [1] [2] [3] [4] 6, [8] [9] [10] [11] It has been estimated that more than 95% of patients are able to find at least one potential 4 of 6 HLA matched cord blood unit on the National Marrow Donor Registry, with the majority finding a potential five of six match. 12 The known advantages of unrelated UCB over unrelated BM are well documented and include increased speed of availability, 13 absence of risk to the donor, reduced transmission of viral illnesses such as CMV, tolerance of HLA disparity between the donor and recipient, 9, 14, 15 better minority representation in UCB banks and reduced risk and severity of acute GVHD when compared to BM grafts. 1, 2, [4] [5] [6] 9, 10, 14, 16, 17 When compared to BM, however, cord blood results in less optimal engraftment kinetics with higher rate of graft failure and slower haematopoietic recovery time. 10, [18] [19] [20] [21] [22] Recent reports suggest that unrelated UCB transplants now account for 20% of all allogeneic transplantations performed in young patients less than 20 years of age. Furthermore, large retrospective studies have shown similar outcomes in paediatric patients with leukaemia using unrelated cord blood compared with matched unrelated BM. 20, 23 We report the results of all unrelated UCB transplantations performed over the last 10 years in the six paediatric transplant centers in Australia and New Zealand. The secondary objectives were to analyse the influence of various demographic, graft and treatment characteristics on the rate of engraftment, probability of engraftment, GVHD, TRM, relapse and survival.
Patients and methods
The Australia and New Zealand Children's Haematology & Oncology Group (ANZCHOG) provided data on all unrelated donor UCB recipients who were 18 years or younger transplanted throughout Australia and New Zealand. Patients with acute leukaemia, other malignancies, BM failure syndromes, immunodeficiency states or metabolic disorders were all eligible for unrelated donor UCB transplantation if (1) a related or unrelated BM donor with no more than one HLA disparity was unavailable or (2) the delay in time to locate a potential unrelated BM donor was thought to be clinically disadvantageous and (3) the patient or patient's parent consented to the transplantation procedure. Transplants were performed in one of six paediatric cancer centers, five located in Australia and one in New Zealand. Patient and treatment characteristics are shown in Table 1 . Median age of the patients was 5.1 years and median weight was 19 kg. Transplant for a haematological malignancy accounted for 74% of patients (n ¼ 96). The most common indication for transplantation was for the treatment of acute leukaemia (ALL, n ¼ 46; AML, n ¼ 29). Thirty-four unrelated UCB transplants were performed for correction of non-malignant diseases including marrow failure (n ¼ 8), immune deficiency (n ¼ 13), metabolic disorders (n ¼ 9) and phagocytic disorders (n ¼ 4).
Patients

HLA typing and unrelated donor selection
Cord units were selected on the basis of best HLAmatching and a critical minimum cell dose at the discretion of the treating physicians and sourced from National and International Public Banks. Class I typing was performed by serological or molecular techniques and Class II typing by molecular techniques. Transplant centers were responsible for obtaining confirmatory HLA typing on recipients. Confirmatory tissue typing on a second sample of the selected cord blood units was performed by the tissuetyping lab associated with the cord blood bank of origin. In this study cohort, 88% of the recipients received a 1-HLA antigen or more mismatched cord unit (Table 1) .
Conditioning regimen and GVHD prophylaxis
The conditioning regimen varied according to the underlying disease and prior therapy (Table 1) . Fifty-three percent of all patients received a TBI-containing regimen and 64% of the malignant disease cohort received TBI (1200-1300 cGy) and CY (120 mg/kg)-containing regimen (n ¼ 55). Of those within the malignant disease cohort who did not receive a TBI-containing regimen, most received a BU and CY-containing regimen (n ¼ 24). Nine patients received a BU and melphalan-containing regimen and two patients received melphalan alone. The majority of patients with a non-malignant disease received a chemotherapyonly conditioning regimen consisting of BU in combination with CY (n ¼ 23). All but 12 patients received antithymocyte globulin (ATGAM) prior to unrelated donor UCB transplantation.
Prophylaxis for acute GVHD consisted mainly of CsA and methylprednisolone (n ¼ 80) or CsA and methylprednisolone and MTX (n ¼ 30) (Table 1) . CsA was initiated on day À2 and continued until day þ 100 before a 10% per week taper was initiated. Methylprednisolone (1 mg/kg intravenously every 8 h) was administered on days 5-7 with a taper thereafter over a 10-day period. MTX (10 mg/m 2 ) was administered intravenously on day 1 and days 3, 6 and 11.
Transplantation of UCB Cryopreserved units of UCB were transported to the transplantation center by air cargo in a dry shipper, previously cooled by liquid nitrogen (temperature oÀ150 1C), before initiation of the conditioning regimen and then maintained in the vapour phase liquid nitrogen at the transplantation center until the day of transplantation. Units are thawed at the bedside and infused intravenously over a 10-to 15-min period without manipulation in the 
Supportive care
Patients were hospitalized in single rooms ventilated with high-efficiency particulate air filtration systems. Patients deemed high risk for the recurrence of CMV received treatment dosing of ganciclovir with CMV Ig during conditioning. Following neutrophil recovery, they received prophylactic or pre-emptive ganciclovir until at least day 100. Documented CMV reactivation or infection shown by antigenemia or molecular PCR testing after transplantation was treated with therapeutic doses of either foscarnet or ganciclovir. Patients at risk for recurrence of herpes simplex received prophylactic i.v. acyclovir. Broad-spectrum empiric antibiotics and antifungal therapy were administered for fever based on institutional protocols. Patients received prophylaxis with co-trimoxazole for Pneumocystis carinii after engraftment. Recombinant human G-CSF was given routinely post transplant to support engraftment.
Haematopoietic engraftment
Neutrophil engraftment was defined as the first of 3 consecutive days when the ANC was equal to or greater than 0.5 Â 10 9 /l. Platelet engraftment was defined as the first day of an unsupported platelet count equal to or greater than 20 Â 10 9 /l, a minimum of 7 days after the last platelet transfusion. Patients who died without evidence of engraftment were censored at the time of death. Patients must have survived a minimum of 21 days to be eligible for analysis of engraftment.
GVHD
Patients were evaluated and considered at risk once there was evidence of neutrophil recovery for the occurrence of acute GVHD. They were evaluated daily during initial hospitalization, at least once weekly after initial discharge during the first 100 days, and at routine follow-up evaluations at the transplant center. Diagnosis of acute GVHD was based on clinical criteria, with histopathologic confirmation when possible. Overall staging was evaluated according to previously published criteria. 24 Only those patients with sustained engraftment of donor haematopoiesis and surviving for more than 100 days after transplant were evaluated for chronic GVHD according to criteria described earlier. 25 
Statistical analysis
The results of the study cohort were analysed as of 1 February 2007, and all survival statistics reflect this date. The median duration of follow-up of surviving patients was 33 months (range, 13-120 months). Baseline characteristics of all patients were summarized using descriptive statistics. Cumulative incidence rates and their 95% confidence intervals (CIs) were estimated for engraftment, grades II-IV and III-IV acute GVHD, TRM and relapse (for patients with malignant diseases). Overall survival (OS), relapse, leukaemia-free survival and other related curves after unrelated UCB transplantation (starting point interval) were evaluated by Kaplan-Meier methods and compared using log-rank test statistics.
Cox proportional hazard models and log-rank test statistics were used to evaluate the univariate and multiple effects of risk factors on outcome. The outcome variables were engraftment, GVHD, TRM, relapse and survival. Recipient's age, weight, diagnosis (malignant vs nonmalignant disease), malignancy risk category, donorrecipient HLA match, conditioning regimen (TBI-containing vs non-TBI-containing), graft cell dose (total nucleated cells (TNCs) and CD34 cells) and development of acute GVHD were all factors considered as potential predictors of outcome. All statistical analyses were performed with SPSS 14.0 for Windows.
For the purposes of these analyses, patients with leukaemia were categorized as having disease and as belonging to a standard risk group (n ¼ 58) regardless of cytogenetic abnormality, if they received their transplantation during a first or second complete remission (CR). By contrast, patients in third or subsequent remission, relapse, or partial remission or with refractory leukaemia at the time of unrelated UCB transplantation were considered to be in the advanced phase and belonging to the high-risk group (n ¼ 17).
Results
Haematopoietic engraftment
The incidence of neutrophil engraftment by day 42 was 83% (95% CI, 0.76-0.90). Six patients engrafted later than day 42 with 89% engraftment by day 60. Median time to achieve an ANC equal to or greater than 0.5 Â 10 9 /l was 23 days (range, 10-55 days). In univariate analysis, the rate of neutrophil engraftment was strongly associated with infused CD34 cell dose (P ¼ 0.004). Those patients receiving an infused CD34 cell dose X1.7 Â 10 5 /kg had a higher probability of neutrophil recovery at 93% as compared with 85% probability of neutrophil engraftment with patients receiving infused CD34 cell doses less than 1.7 Â 10 5 /kg (P ¼ 0.004) (Figure 1) . Furthermore, the time to engraftment was significantly faster with higher infused CD34 cell dose, with a median time of 18 days (95% CI, range16-20 days) for those patients receiving an infused CD34 cell dose X1.7 Â 10 5 /kg versus a median time of 26 days (95% CI, range 22-29 days) for those receiving an infused CD34 cell dose o1.7 Â 10 5 /kg (P ¼ 0.008). Although neutrophil engraftment was strongly associated with infused CD34 cell dose, the association with infused nucleated cell dose (o3.0 Â 10 7 /kg vs 43.0 Â 10 7 /kg) was not statistically significant (P ¼ 0.45). Similarly, on univariate analysis, there was no impact of HLA disparity, diagnosis or conditioning regimen on neutrophil engraftment ( Table 2 ). The overall probability of platelet engraftment was 78%. The incidence of platelet engraftment by day 60 was 55%. The median time to achieve platelet engraftment was 56 days (range, 20-185 days). In univariate analysis, the rate of engraftment of platelets was not associated with infused CD34 cell dose or infused nucleated cell dose. Similarly, there was no impact of HLA disparity, diagnosis or conditioning regimen on platelet engraftment (data not shown). In Cox regression analysis, neutrophil engraftment (Table 3) was associated with CD34 cell dose. There was no association with age, diagnosis, infused TNC dose, HLA match, TBI-containing regimen or year of transplant. In contrast, there was no association between CD34 cell dose or other variables with platelet engraftment.
Acute and chronic GVHD Acute GVHD occurred in 81 patients and was scored as grade I (n ¼ 29), grade II (n ¼ 32), grade III (n ¼ 5), or grade IV (n ¼ 15) disease. By day 100 after transplantation, incidences of grades II-IV and grades III-IV acute GVHD were 0.41 (CI, 0.32-0.50) and 0.18 (CI, 0.10-0.26), respectively. Sixty percent of the patients had either nil or grade I acute GVHD. When acute GVHD was present, the skin and lower gastrointestinal tract were the organs most likely to be affected. In univariate analysis, there was no association between occurrence and severity of GVHD with any predictor, including HLA-match (P ¼ 0.592) and infused nucleated cell dose (P ¼ 0.423). The incidence of chronic GVHD was low, with only 7 cases reported at a median follow-up of 47 months (range, 22-82 months).
Treatment-related mortality
The incidence of TRM at 100 days and 1 year after unrelated donor UCB transplantation was 25% (CI, 0.17-0.0.33) and 32% (CI, 0.24-0.40), respectively ( Figure 2) . In univariate analyses, the development of grades III-IV acute GVHD (P ¼ 0.004) was associated with increased TRM. In multivariate analyses, the development of grades III-IV acute GVHD was again associated with increased TRM; RR 4.86 (95% CI, 1.21-19.59). There was no association in multivariate analysis between TRM and other factors including age, HLA match, nucleated or CD34 cell dose, diagnosis (malignancy vs non-malignancy), malignancy risk group or conditioning regimen (TBI vs non-TBI containing regimen).
Relapse
Haematological relapse was detected between 39 and 1024 days (median, 289 days) after transplantation in 14 of 96 patients treated for malignant disease. The cumulative incidence of relapse was 25% (CI, 0.12-0.37) at 2 years. For all patients with ALL (n ¼ 46), the incidence of relapse at 5 years was 33% (CI, 0.14-0.52; Figure 3 ). The incidence of relapse at 5 years for standard risk patients was 32% (CI, 0.13-0.51). For high-risk patients, one of 10 patients relapsed. For all patients with AML (n ¼ 29), the incidence Figure 3 ). Three of 7 (42.9%) patients in CR3 or relapse status at the time of transplantation relapsed; 2 of 22 (9.1%) patients in CR1 or CR2 relapsed. In Cox regression analyses, relapse was not associated with cell dose, HLA match, acute GVHD or clinical remission status at the time of transplantation (data not shown).
Survival
With a median follow-up of surviving patients of 21 months (range, 1-108 months), the cumulative proportions surviving at 1 year and 5 years after unrelated donor UCB transplantation were 61% (CI, 0.52-0.70) and 45% (CI, 0.34-0.56) (Figure 4a ). In transplant recipients with malignant and non-malignant disease, the proportions . Favourable survival outcomes were observed in univariate analysis in recipients with lower weights (P ¼ 0.048), whereas inferior survival was noted in patients with severe acute GVHD (0.007). It can be noted that other potential risk factors such as the recipient's age (P ¼ 0.167), disease (P ¼ 0.107), total nucleated (P ¼ 0.310) or CD34 cell dose (P ¼ 0.501), and conditioning regimen (TBI or non-TBI containing regimen, P ¼ 0.461) did not reach statistical significance. There was a trend for an association with the survival and leukaemia risk group, with the standard risk group having improved survival (P ¼ 0.07). In multivariate analysis, only the development of grades III-IV acute GVHD had a significant impact on survival (P ¼ 0.002), whereas those without severe acute GVHD had more favourable outcome (Table 2) .
In this series, 58 patients died. Death was most frequently associated with opportunistic infection (n ¼ 22) and relapse of malignant disease (n ¼ 16), with the majority of deaths occurring less than 12 months after transplantation ( Figure 5 ). The infectious related deaths included: CMV (n ¼ 7), aspergillosis (n ¼ 4), bacterial sepsis (n ¼ 8) and other viruses (n ¼ 3). Patients may have had more than one cause of death, for example, GVHD and infection. Other causes of death included acute GVHD (n ¼ 11), multi-organ failure (n ¼ 9), hepatic veno-occlusive disease (n ¼ 6), graft failure (n ¼ 1), ARDS (n ¼ 1), liver failure (n ¼ 1), heart failure (n ¼ 1), cor pulmonale (n ¼ 1) and leukoencephalopathy (n ¼ 1).
Discussion
This large multi-institutional retrospective analysis supports the use of unrelated UCB as an alternative stem cell source for the treatment of paediatric malignant and nonmalignant diseases. UCB is enriched with haematopoietic progenitor cells and contains sufficient numbers of HSCs to reconstitute most paediatric patients. 1, 2, 4, 6, 8, 9, 17, 19, [26] [27] [28] [29] [30] [31] [32] [33] Most studies have shown that the nucleated cell dose is of paramount importance for haematopoietic recovery, 2, 4, 6, 14, 16, 17 Wagner et al. 10 have also shown the CD34 cell dose as being a significant variable not only for haematopoietic recovery but also for survival. The importance of CD34 cell dose has been replicated in other studies. 11, 34 Interestingly, unlike unrelated BM or peripheral blood stem cells, the effect of HLA disparity appears to have a less convincing impact on neutrophil engraftment in unrelated UCB transplantation. 10 In our study cohort, the Kaplan-Meier estimate of neutrophil engraftment was 89% overall, which is similar to that reported in other studies. 1, 2, 10, 14, 20, 34 Similar to Wagner et al., 10 our results also showed the importance of the CD34 cell dose; UCB recipients who received a higher infused CD34 cell dose (X1.7 Â 10 5 /kg) had a higher probability of engraftment. In addition, the time to neutrophil engraftment was significantly quicker with a higher infused CD34 cell dose. The duration of neutropenia was reduced by a median of 8 days in recipients of cord units with a higher CD34 cell count. In contrast to other Unrelated cord blood transplant in Australia and New Zealand TE Petterson et al studies, however, 2, 4, 6, 14, 16, 17 we found no impact on the probability or speed of neutrophil engraftment with larger infused TNC doses. Similarly, there was no impact of HLA disparity, diagnosis or conditioning regimen on neutrophil engraftment.
One advantage of UCB is its apparent reduced alloreactivity when compared with BM or peripheral bloodderived haematopoietic stem cells. In most reports, the incidence of acute GVHD after UCBT is lower than that expected for BMT. 2, 6, 9, 10, 17, 23, 28 The influence of HLA mismatch is less consistent, with some studies showing a higher risk of acute GVHD with greater HLA disparity. 1, 9, 17 Our results are in keeping with the published literature with a low incidence of acute GVHD: 41% of grades II-IV and 18% of grades III-IV acute GVHD and no association with HLA disparity. Comparative matched pair analyses of UCB recipients with BMT recipients have also supported this finding. 21, 22 However, a recent study reported by Eapen et al. 20 compared the results of 282 BM recipients with 503 unrelated UCB transplants performed in children between 1995 and 2003. They found a similar incidence of acute GVHD after transplants of matched or mismatched cord blood and matched or mismatched BM.
Most series report the incidence of chronic GVHD following UBCT to be in the range of 9-38%. 2, 6, 16, 21, 28, 29, 35 There appears to a significantly lower risk of chronic GVHD in recipients of HLA-identical sibling UCB. However, in the unrelated setting, most comparative studies fail to demonstrate a statistical difference between UCB and BM. 2, 16, 21, 22, 35 Only seven patients in our study cohort developed chronic GVHD. However, as with other studies, our follow-up may be too short to draw any definite conclusions.
Survival following UCBT reported in studies to date range between 29 and 58%. 2, 10, 11, 21, 23, 36 However, data comparisons between studies are difficult as there is heterogeneity in eligibility criteria, underlying diagnosis, treatment, supportive care plans and definitions of end points. OS in our study was 61% at 1-year post transplant and 45% at 5-years post transplant, which is comparable to earlier reports. Survival after unrelated UCBT has been found to be influenced by age, HLA match, higher cell doses, disease status at the time of transplant and treatment indication (malignant or non-malignant disease). 6, 10, 11, 21, 23 Additionally, when comparing UCB recipients with BM recipients, studies indicate that survival after 1-2 HLAmismatched unrelated UCBT are comparable with those observed after HLA-matched BMT. [20] [21] [22] In our study, HLA-matching and nucleated cell dose together appeared to influence survival. Inferior survival was seen with HLAmismatched (three out of six and four our six) cord grafts with low infused nucleated cell doses when compared to similarly HLA-mismatched grafts with higher infused nucleated cell doses (28 vs 58%, P ¼ 0.422). Furthermore, although nucleated cell dose was not associated with OS in multivariate analysis, there was improved survival seen in those patients who did engraft with higher nucleated cell doses (60 vs 22%, P ¼ 0.047). The TNC dose has been suggested to have an influence on lymphoid reconstitution and hence immune recovery. 37 As infection remains a serious concern after allogeneic transplantation, an explanation for reduced survival in those patients who engrafted, but with lower TNC doses, may be that of delayed immune reconstitution. We found no effect of age, diagnosis, CD34 cell dose or conditioning regimen on survival. Not unexpectedly, a history of severe acute GVHD was associated with inferior survival.
TRM remains a principal obstacle to successful transplantation outcome in recipients of unrelated allogeneic transplants. TRM for our entire study cohort was 25% at day 100 and 32% at 2 years, which is comparable to other studies. 2, 10, 11, 21, 23, 34, 36 TRM in adult recipients of UCB after a myeloablative regimen has been reported to be as high as 60%. 7, 10, 14, 17, 19, [30] [31] [32] [33] Comparing UCBT to BMT, Rocha et al. 22 compared the outcomes of 541 children transplanted for the treatment of acute leukaemia receiving a UCBT (n ¼ 99), unmanipulated BMT (n ¼ 262), or T-cell-depleted BMT (n ¼ 180). UCB recipients were observed to have a higher TRM within the early period after transplantation. Eapen et al. 20 reported recently that TRM after a 1-HLA disparate UCBT with a high cell dose or fully matched cord was similar when compared with a matched BMT. Rocha et al.'s findings may be explained by the fact that UCB recipients had higher risk features (for example, early relapse before transplantation, short interval from diagnosis to transplantation and previous transplantation) when compared to BMT groups. 38 It has also been suggested that a low CD34 cell dose may have contributed to the higher TRM in their UCBT group. 39 Wagner et al.
10
found that there was a critical threshold (1.7 Â 10 5 /kg) below which patients had a very high TRM.
As with unrelated donor BMT, infection and relapse remain the most common cause of death after UCB transplantation. If alloreactive response is lower after UCBT, and there is decreased GVHD, this raises the concern of decreased GVL effect. Accordingly, it has been postulated that the relapse rate may be increased. However, the incidence of relapse after UCBT is similar to that in recipients of unmanipulated BM. 20, 22, 35 In fact, Eapen et al.
20
report lower relapse rates after two-antigen HLA-mismatched cord blood transplants. In our series, we found the 5-year relapse rates for ALL and AML to be 33 and 22% respectively, which are comparable to these previous studies. Our large series would certainly support the selection of cord units with a greater than or equal to 1.7 Â 10 5 /kg CD34 cell dose and those that are matched or 1-HLA mismatched, to lower TRM and improve survival. Furthermore, the progenitor cell content has been suggested as an improved predictor of transplant outcomes, 25 and the TNC dose has also been suggested to have an influence on lymphoid reconstitution. 40 Similar to others, we are investigating alternative strategies to increase the UCB cell dose, such as the double unit UCB transplant, ex vivo expansion 40, 41 and co-infusion of mesenchymal stem cells. 37, 42, 43 
